What's Happening?
Delphi Diagnostics has appointed Eric Lindquist as its new Chief Financial Officer, effective April 1, 2026. Lindquist brings extensive experience in the oncology and life sciences sectors, having previously held leadership roles at InnoSIGN and Celcuity.
At Delphi, he will oversee financial strategy as the company advances its Endocrine Activity Index (EAI) test, which aids in treatment decision-making for breast cancer. Lindquist's appointment comes at a pivotal time for Delphi, as it seeks to expand access to its EAI test and develop next-generation diagnostics. His background in commercialization and strategic finance is expected to be instrumental in guiding the company's growth and innovation efforts.
Why It's Important?
Lindquist's appointment is a strategic move for Delphi Diagnostics as it positions itself to become a leader in personalized breast cancer treatment. The EAI test, which provides prognostic and predictive information for breast cancer treatment, represents a significant advancement in personalized medicine. By enhancing treatment decision-making, Delphi aims to improve patient outcomes and reduce the burden of breast cancer. Lindquist's expertise in financial strategy and commercialization will be crucial in scaling the company's operations and ensuring the widespread adoption of its diagnostic tools. This development highlights the growing importance of personalized diagnostics in the healthcare industry.
